Research Desk Line-up: Jazz Pharma Post Earnings Coverage
LONDON, UK / ACCESSWIRE / November 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Adaptimmune Therapeutics PLC (NASDAQ: ADAP), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=ADAP. The Company announced on November 10, 2017, that it would be presenting progress posters of two trials which will outline the study designs for ongoing clinical trials with MAGE-A4 and NY-ESO SPEAR T-cells. These progress posters would be presented at the 2017 The Society for Immunotherapy of Cancer (SITC) annual meeting scheduled from November 08, 2017, to November 12, 2017, at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) for due-diligence and potential coverage as the Company announced on November 07, 2017, its financial results for Q3 2017 and updated financial guidance for 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Jazz Pharma when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ADAP; also brushing on JAZZ. Go directly to your stock of interest and access today's free coverage at:
The progress posters of the two trials will summarize the study designs for Adaptimmune's ongoing MAGE‑A4 multi‑tumor study in urothelial (bladder), melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, and gastric cancers; and, the combination study with NY-ESO and NY‑ESO and KEYTRUDA® (pembrolizumab) in multiple myeloma.
Outline of Study Design for MAGE-A4 SPEAR T-cells
The MAGE-A4 SPEAR T-cells clinical trial is an open-label, non-randomized pilot study that evaluates the safety, tolerability, and antitumor activity of MAGE-A4 SPEAR T-cells in patients with HLA-A*02 and MAGE-A4 positive inoperable locally advanced or metastatic tumor(s). The dosage escalation study uses a modified 3+3 design wherein there will be three groups of patients. In Group 1 there will be 3 to 6 patients who will be treated using a dose of 100 million transduced SPEAR T-cells and will have a 21-day interval for safety review. The Group 2 will have 3 to 6 patients who will be treated using a dose of 1 billion transduced SPEAR T-cells, 7-day interval for safety review and the third Group 3 will also have 3 to 6 patients who will be treated using a dose of 1-5 billion transduced SPEAR T-cells, 7-day interval for safety review.
The patient candidates in the clinical trial must be over 18 years, have HLA-A*02 positive, have MAGE-A4 positive inoperable locally advanced or metastatic tumor(s) at ≥1+ intensity in ≥ 10% of tumor cells MAGE-A4 expression by immunohistochemistry (IHC), have ECOG status 0 or 1 and adequate organ function. They would follow the Lymphodepletion regimen wherein they will be given fludarabine (30 mg/m2/day) and cyclophosphamide (600 mg/m2/day) for 3 days.
The efficacy of the trial will be assessed by overall response rate, time to response, duration of response, progression-free survival, and overall survival at weeks 4, 8, and 12, month 6, and then every 3 months until confirmation of disease progression. The study is open and ongoing.
Outline of Study Design for NY ESO SPEAR T-cells with or without KEYTRUDA® in multiple myeloma
This trial is an open-label, randomized pilot study which will evaluate the safety, tolerability, and antitumor activity of NY-ESO SPEAR T-cells with or without KEYTRUDA® in patients with multiple myeloma. Patients who are eligible for this study would be randomly assigned either of the two treatment groups - NY-ESO SPEAR T-cells alone (Arm 1) or NY-ESO-1 SPEAR T-cells in combination with KEYTRUDA® (Arm 2). The clinical study will have total 20 patients and each group is expected to have 10 patients. Those eligible patients who do not receive the T‑cell infusion may be replaced.
The patient candidates in the clinical trial must be over 18 years, HLA-A*02:01, *02:05, or *02:06 positive, have histologically confirmed diagnosis of multiple myeloma with either primary refractory or relapsed/refractory disease expressing NY-ESO-1 and/or LAGE-1a, they should have received prior therapies including IMiD and a proteasome inhibitor as separate lines or a combined line of therapy; have ECOG status 0 or 1; and adequate organ function. The patients would be following the Lymphodepletion regimen fludarabine (30 mg/m2/day) and cyclophosphamide (600 mg/m2/day) for 3 days, followed by granulocyte-colony stimulating factor. For patients in Arm 2, KEYTRUDA® will be administered every 3 weeks, starting at week 3 following T-cell infusion until week 108. The target dosage is dose of 1 – 8 × 109 transduced SPEAR T-cells. The efficacy of the trial will be assessed by the International Myeloma Working Group (IMWG) Uniform Response Criteria. Overall response rate, time to response, duration of response, progression-free survival, and overall survival will be determined. The study is open and enrolling.
About Adaptimmune Therapeutics PLC
Adaptimmune is a clinical-stage biopharmaceutical Company and a leader in the TCR T-cell therapy space focused on developing novel cancer immunotherapy products. The Company has developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors (TCRs), and produce TCR therapeutic candidates called SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets - and destroy cancer including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10 and AFP across several solid tumor indications. GlaxoSmithKline Plc (NYSE:GSK) exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune's NY-ESO SPEAR T-cell therapy program in September 2017. The process of transition is in progress. The Company is located in Philadelphia, US and Oxfordshire, UK.
Last Close Stock Review
At the closing bell, on Monday, November 13, 2017, Adaptimmune Therapeutics' stock slipped 3.70%, ending the trading session at $7.80. A total volume of 162.90 thousand shares have exchanged hands. The Company's stock price soared 50.58% in the last three months, 40.79% in the past six months, and 55.69% in the previous twelve months. Moreover, the stock skyrocketed 92.59% since the start of the year. The stock currently has a market cap of $4.37 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily